A5085249714- SARS-CoV-2 and COVID-19 Research
- Advanced biosensing and bioanalysis techniques
- Trypanosoma species research and implications
- Biosensors and Analytical Detection
- Research on Leishmaniasis Studies
- vaccines and immunoinformatics approaches
- Parasites and Host Interactions
- Viral gastroenteritis research and epidemiology
- Animal Virus Infections Studies
- Advanced Biosensing Techniques and Applications
- Bacillus and Francisella bacterial research
- Plasmonic and Surface Plasmon Research
- Helminth infection and control
- Transgenic Plants and Applications
- Advanced Chemical Sensor Technologies
- Food Allergy and Anaphylaxis Research
- Viral Infections and Immunology Research
- Parasite Biology and Host Interactions
- Virus-based gene therapy research
- Metabolism and Genetic Disorders
- Advanced Fiber Optic Sensors
- Microfluidic and Capillary Electrophoresis Applications
- Photonic and Optical Devices
- Antibiotics Pharmacokinetics and Efficacy
- Gout, Hyperuricemia, Uric Acid
Baylor College of Medicine
2016-2025
Texas Children's Hospital
2016-2025
Children's Center
2021
Center for Children
2021
Hospital for Tropical Diseases
2020
Sabin Vaccine Institute
2014-2017
University of Houston
2012-2015
KU Leuven
2008-2012
BioElectronics (United States)
2010
Sensors (United States)
2010
There is an urgent need for accessible and low-cost COVID-19 vaccine suitable low- middle-income countries. Here, we report on the development of a SARS-CoV-2 receptor-binding domain (RBD) protein, expressed at high levels in yeast (Pichia pastoris), as candidate against COVID-19. After introducing two modifications into wild-type RBD gene to reduce yeast-derived hyperglycosylation improve stability during protein expression, show that recombinant RBD219-N1C1, equivalent (RBD219-WT) vitro...
Ongoing SARS-CoV-2 vaccine development is focused on identifying stable, cost-effective, and accessible candidates for global use, specifically in low middle-income countries. Here, we report the efficacy of a rapidly scalable, novel yeast expressed specific receptor-binding domain (RBD) based rhesus macaques. We formulated RBD immunogen alum, licensed an emerging alum adsorbed TLR-7/8 targeted, 3M-052-alum adjuvants. The RBD+3M-052-alum adjuvanted promoted better binding effector...
We have selected aptamers binding to lysozyme from a DNA library using capillary electrophoresis-systematic evolution of ligands by exponential enrichment. During the selection process dissociation constant ssDNA pool decreased micromolar low nanomolar range within five rounds selection. The final aptamer had 2.8 ± 0.3 nM, 6.1 0.5 and 52.9 9.1 nM as determined fluorescence anisotropy, surface plasmon resonance affinity electrophoresis respectively. were successfully challenged for...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has killed more than 4 million humans globally, but there is no bona fide Food and Drug Administration-approved drug-like molecule to impede the COVID-19 pandemic. The sluggish pace of traditional therapeutic discovery poorly suited producing targeted treatments against rapidly evolving viruses. Here, we used an affinity-based screen billion DNA-encoded molecules en masse identify a potent class virus-specific inhibitors SARS-CoV-2...
SARS-CoV-2 protein subunit vaccines are currently being evaluated by multiple manufacturers to address the global vaccine equity gap, and need for low-cost, easy scale, safe, effective COVID-19 vaccines. In this paper, we report on generation of receptor-binding domain RBD203-N1 yeast expression construct, which produces a recombinant capable eliciting robust immune response protection in mice against challenge infections. The antigen was expressed Pichia pastoris X33. After fermentation at...
We conducted preclinical studies in mice using a yeast-produced SARS-CoV-2 RBD subunit vaccine candidate formulated with aluminum hydroxide (alum) and CpG deoxynucleotides. This formulation is equivalent to the CorbevaxTM that recently received emergency use authorization by Drugs Controller General of India. compared immune response vaccinated RBD/alum + CpG. also evaluated immunized boosted RBD/alum. Mice were twice intramuscularly at 21-day interval. Compared two doses /alum formulation,...
Introduction The development of a yeast-expressed recombinant protein-based vaccine technology co-developed with LMIC producers and suitable as COVID-19 for global access is described. proof-of-concept developing SARS-CoV-2 spike protein receptor-binding domain (RBD) antigen yeast-derived described.Areas Covered Genetic Engineering: strategy presented the design genetic modification used during cloning expression in yeast system. Process Assay Development: A summary how scalable,...
Chagas disease (CD) (American trypanosomiasis caused by Trypanosoma cruzi) is a parasitic endemic in 21 countries South America, with increasing global spread. When administered late the infection, current antiparasitic drugs do not prevent onset of cardiac illness leading to chronic Chagasic cardiomyopathy. Therefore, new therapeutic vaccines or immunotherapies are under development using multiple platforms. In this study, we assessed feasibility developing an mRNA-based CD vaccine...
Pseudoviruses are recombinant, replication-incompetent, viral particles designed to mimic the surface characteristics of native enveloped viruses. They a safer, and cost-effective research alternative live With potential emergence next major infectious disease, more vaccine scientists must become familiar with pseudovirus platform as development tool mitigate future outbreaks.
Chagas disease affects 6 to 7 million people worldwide, resulting in significant burdens and health care costs countries of endemicity. Chemotherapeutic treatment is restricted two parasiticidal drugs, benznidazole nifurtimox. Both drugs are highly effective during acute but only minimally chronic fraught with adverse clinical effects. In experimental models, vaccines can be used induce parasite-specific balanced TH1/TH2 immune responses that effectively reduce parasite associated...
A therapeutic vaccine for human Chagas disease is under development by the Sabin Vaccine Institute Product Development Partnership. The aim of to significantly reduce parasite burden Trypanosoma cruzi in humans, either as a standalone product or combination with conventional chemotherapy. Vaccination mice Tc24 formulated monophosphoryl-lipid (MPLA) adjuvant results Th1 skewed immune response elevated IgG2a and IFNγ levels statistically significant decrease parasitemia following T. challenge....
Chagas disease, caused by the parasite Trypanosoma cruzi, develops into chronic Chagas' cardiomyopathy in ~30% of infected individuals, characterized conduction disorders, arrhythmias, heart failure, and even sudden cardiac death. Current anti-parasitic treatments are plagued significant side effects poor efficacy phase disease; thus, there is a pressing need for new treatment options. A therapeutic vaccine could bolster protective TH1-mediated immune response, thereby slowing or halting...
Tc24 is a Trypanosoma cruzi-derived flagellar protein that, when formulated with TLR-4 agonist adjuvant, induces balanced immune response in mice, elevating IgG2a antibody titers and IFN-γ levels. Furthermore, vaccination the recombinant can reduce parasite levels improve survival during acute infection. Although some mRNA vaccines have been proven to elicit stronger than vaccines, they not used against T. cruzi. This work evaluates immunogenicity of heterologous prime/boost regimen using...